Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H19FN6O2 |
| Molecular Weight | 394.4023 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | meso |
SHOW SMILES / InChI
SMILES
ONC(=O)C1=CN=C(N=C1)N2C[C@H]3[C@@H](C2)[C@@H]3NCC4=NC5=CC=C(F)C=C5C=C4
InChI
InChIKey=QRGHOAATPOLDPF-VQFNDLOPSA-N
InChI=1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18+
| Molecular Formula | C20H19FN6O2 |
| Molecular Weight | 394.4023 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. | 2012-05-01 |
|
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | 2011-07-14 |
|
| Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. | 2010-12-23 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 21:25:16 GMT 2025
by
admin
on
Tue Apr 01 21:25:16 GMT 2025
|
| Record UNII |
YTL7A418KQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
676118
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
||
|
FDA ORPHAN DRUG |
675818
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
||
|
FDA ORPHAN DRUG |
733420
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10911
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
1235859-13-8
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
SUPERSEDED | |||
|
YTL7A418KQ
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
DB15419
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
49857317
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
300000005934
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
1256448-47-1
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
C78475
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY | |||
|
914937-68-1
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
EF-146
Created by
admin on Tue Apr 01 21:25:16 GMT 2025 , Edited by admin on Tue Apr 01 21:25:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->WEAK INHIBITOR |
IC50
|
||
|
TARGET->WEAK INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|